In contrast, mesalazin therapy leads to a growth arrest due to higher CDHR5 expression in colorectal carcinoma (CRC) by inducing an increased transcription of the cyclin-dependent kinase inhibitor (p21waf-1) gene [24]. This evidence concerns the gene CDKN3 and colorectal carcinoma.